Capital World Investors
JAZZ icon

Capital World Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capital World Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$650M Buy
2,697,610
+24,234
+0.9% +$5.31M 0.08% 192
2026
Q1 		$505M Buy
2,673,376
+6,774
+0.3% +$1.18M 0.07% 204
2025
Q4 		$453M Buy
2,666,602
+111,735
+4% +$17.1M 0.06% 208
2025
Q3 		$337M Buy
2,554,867
+10,345
+0.4% +$1.24M 0.05% 231
2025
Q2 		$270M Buy
2,544,522
+616,728
+32% +$67M 0.04% 251
2025
Q1 		$239M Buy
1,927,794
+4,452
+0.2% +$581K 0.04% 255
2024
Q4 		$237M Buy
1,923,342
+104,195
+6% +$12.3M 0.04% 259
2024
Q3 		$203M Sell
1,819,147
-200,422
-10% -$22M 0.03% 280
2024
Q2 		$216M Buy
2,019,569
+591,709
+41% +$65.1M 0.04% 269
2024
Q1 		$172M Buy
+1,427,860
New +$175M 0.03% 291

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors's JAZZ Position: Q2 2026 in Review

Capital World Investors increased its Jazz Pharmaceuticals (JAZZ) stake by 0.91% in Q2 2026, buying an estimated $5.31M and bringing the position to 2,697,610 shares worth $650M. The position accounts for 0.08% of the portfolio, ranked #192.

Capital World Investors first reported a position in JAZZ in Q1 2024 and has held it in 10 quarters since. 488 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Capital World Investors held 2,697,610 shares of Jazz Pharmaceuticals worth $650M as of Q2 2026.
  • Capital World Investors bought 24,234 Jazz Pharmaceuticals shares in Q2 2026, an estimated $5.31M.
  • Jazz Pharmaceuticals made up 0.08% of Capital World Investors's portfolio in Q2 2026, its #192 holding.
  • Capital World Investors first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 488 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.